X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The acquisition will strengthen Merck's immunology pipeline by adding diversity of portfolio including, PRA023 (tulisokibart), a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $10,800.0 million Upfront Cash: $10,800.0 million
Deal Type: Acquisition April 16, 2023
Details:
PRA023 is a humanized IgG1 mAb that has been shown to block the tumor necrosis factor (TNF)-like ligand 1A (TL1A), a target associated with both intestinal inflammation and fibrosis. It is currently in phase 2a clinical trial for crohn's disease.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
Prometheus intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments to fund the development of PRA023 (a monoclonal antibody against cytokine TL1A), PRA052 and its other research and development programs.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2022
Details:
Prometheus intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments to fund the development of PRA023, PRA052 and its other research and development programs.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 07, 2022
Details:
PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity and has the potential to substantially improve outcomes for moderate-to-severe IBD patients predisposed to increased TL1A expression.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF.
Lead Product(s): PRA052
Therapeutic Area: Gastroenterology Product Name: PRA052
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
PRA023, is a monoclonal antibody against cytokine TL1A, a target associated with both intestinal inflammation and fibrosis,for the treatment of Ulcerative Colitis.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
PRA023 is an IgG1 humanized mAB block TNF-like ligand 1A, binds both soluble and membrane-associated human TL1A with high affinity and specificity and has potential to substantially improve outcomes for IBD patients predisposed to increased TL1A expression.
Lead Product(s): PRA023
Therapeutic Area: Gastroenterology Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
PRA023 is an IgG1 humanized monoclonal antibody (mAb) that has been shown to block tumor necrosis factor like ligand 1A (TL1A), binds both soluble and membrane-associated human TL1A with high affinity and specificity and has the potential to improve outcomes for IBD patients.
Lead Product(s): PRA023
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRA023
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
Based on positive topline Phase 1 results, US FDA has granted Fast Track Designation for PRA023, for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease to improve clinical outcomes for patients with this debilitating disease.
Lead Product(s): PRA023
Therapeutic Area: Immunology Product Name: PRA023
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
